Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Genmab Acquires Merus in $8B Deal to Advance Head and Neck Cancer Bispecific Antibody

September 30, 2025

Danish biotech Genmab is acquiring Netherland-based Merus for approximately $8 billion in an all-cash transaction, aiming to fully own Merus’ late-stage bispecific antibody petosemtamab, a...

CRISPR’s Evolution: RNA Splitting Mechanism Traced to Type V System Origins

September 30, 2025

A collaborative team led by Caixia Gao at the Chinese Academy of Sciences revealed the evolutionary origin of Type V CRISPR-Cas systems through the discovery of transposon-CRISPR intermediates...

Advanced AI Differentiates Glioblastoma During Surgery for Real-Time Diagnosis

September 30, 2025

Harvard Medical School researchers developed an artificial intelligence tool capable of real-time differentiation between glioblastoma and mimicking brain tumors during surgical procedures. This...

UniQure’s Gene Therapy Slows Huntington’s Disease Progression by 75% in 36-Month Data

September 30, 2025

UniQure reported compelling 36-month clinical data showing its gene therapy candidate AMT-130 significantly slowed Huntington’s disease progression—meeting the primary endpoint with a 75%...

Polymyxin B Antibiotic Kills Bacteria Only When Cells Are Metabolically Active

September 30, 2025

A University College London-led research team elucidated the mechanism behind polymyxin B’s bactericidal action, revealing it disrupts bacterial outer membranes in an energy-dependent manner....

NeuroKaire Launches Precision Depression Test Using Stem Cell-Derived Neurons

September 30, 2025

Israeli firm NeuroKaire has commercialized a laboratory-developed test that assesses major depressive disorder through analysis of patient-derived frontal cortical neurons differentiated from...

PHIL Launches Direct-to-Patient Platform to Enhance Access and Affordability in Pharma

September 30, 2025

PHIL unveiled its direct-to-patient 2.0 platform designed to improve pharmaceutical access and adherence by integrating coverage-first workflows, telemedicine, prescription fulfillment, real-time...

STAT+: FDA’s Top Regulator Criticizes Voclosporin Safety on LinkedIn

September 30, 2025

George Tidmarsh, the director of FDA’s Center for Drug Evaluation and Research, publicly questioned the safety and clinical benefit of voclosporin, a 2021-approved drug for lupus nephritis, on his...

Long-Term PSA Screening Boosts Early Prostate Cancer Detection and Outcomes

September 30, 2025

A 12-year cohort study in Korea involving over 5,400 prostate cancer patients demonstrated that sustained prostate-specific antigen (PSA) screening leads to earlier cancer detection and lowers...

Genmab’s $8B Merus Acquisition Fuels Cancer Pipeline Expansion

September 30, 2025

Danish biopharma Genmab is acquiring Dutch biotech Merus for approximately $8 billion in cash to gain full ownership of Merus’ late-stage cancer assets, including the bispecific antibody...

Advances in AI and Molecular Technologies Enhance Drug Discovery

September 30, 2025

Cutting-edge AI-driven tools and molecular platforms are transforming drug development and diagnostics. Cadence Molecular Sciences launched ROCS X, an AI-powered molecular screening software...

Breakthroughs in Cancer Therapeutics and Diagnostics

September 30, 2025

Novel therapeutic candidates and diagnostics advance cancer care. Star Therapeutics secured $125 million to push its monoclonal antibody VGA039 targeting bleeding disorders with potential in von...

Polymyxin B’s Energy-Dependent Mechanism Illuminates Antibiotic Action

September 30, 2025

New research reveals polymyxin B, a last-resort antibiotic against multidrug-resistant Gram-negative bacteria, kills only metabolically active cells by inducing detrimental outer membrane...

COVID-19 Vaccine Boosters Show Durable Immunity in Long-Term Study

September 30, 2025

A rigorous 24-month longitudinal study in Indonesia compared the immunogenicity of fractional versus standard dose COVID-19 vaccine boosters in healthy adults. Published in Nature Communications,...

Innovations in Radiation Therapy Match Surgery Outcomes in Lung Cancer

September 30, 2025

A landmark decade-long clinical trial has established that stereotactic radiation therapy delivers survival outcomes on par with surgical resection in early-stage non-small cell lung cancer...

New mRNA Vaccine Shows Promise in Treating Macular Degeneration

September 30, 2025

Japanese researchers developed an mRNA vaccine that suppresses pathological retinal neovascularization underlying age-related macular degeneration in mouse models. This intramuscular vaccine...

Direct-to-Patient Platforms Respond to Drug Pricing Pressures

September 30, 2025

With US drug pricing reforms looming, pharmaceutical firms have introduced direct-to-patient models to enhance medication accessibility and affordability. PHIL launched its Direct-to-Patient 2.0...

FDA Leadership Change and Regulatory Policy Shifts in Drug Approval

September 30, 2025

Dr. Anthony Letai, a renowned oncologist and cell death pathway expert, has been appointed director of the National Cancer Institute, promising a renewed focus on biomarker discovery and...

Exercise and Immune Recovery in Post-COVID Syndrome

September 30, 2025

A randomized controlled trial presented at the European Respiratory Society Congress demonstrated that structured exercise significantly recalibrates immune function in individuals with post-COVID...

Genmab's $8B Merus Acquisition Transforms Head and Neck Cancer Pipeline

September 30, 2025

Genmab has finalized an $8 billion all-cash acquisition of Dutch biotech Merus, securing rights to its phase III-stage bispecific antibody, petosemtamab, targeting head and neck cancer....